MedTrace Logo

Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

NCT03212807 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-09-13

No results posted yet for this study

Summary

PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL

Patients with relapsed refractory subtypes of DLBCL who fulfill the inclusion / exclusion criteria will be recruited to this trial and treated in this open label, phase 2 trial with the PDL1 inhibitor Durvalumab and Lenalidomide. The combination treatment will be given from the time of recruitment for 6 months when Lenalidomide will be stopped but Durvalumab will continue for a total of 2 years. Response will be assessed by PET / CT scans as per standard lugano criteria.

Conditions

  • EBV Related Non-Hodgkin's Lymphoma
  • Primary CNS Lymphoma
  • Primary Testicular Lymphoma

Interventions

DRUG

Durvalumab

Investigational Medicinal Product

DRUG

Lenalidomide

Investigational Medicinal Product

Sponsors & Collaborators

  • National Cancer Center Singapore, Singapore

    collaborator UNKNOWN

  • National University Hospital, Singapore

    collaborator OTHER

  • Raffles Hospital, Singapore

    collaborator OTHER

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Chandramouli Nagarajan, MD FRCPath · Singapore General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-31
Primary Completion
2021-02-28
Completion
2023-08-31
FDA Drug
Yes

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03212807 on ClinicalTrials.gov